Thermo Fisher Scientific Introduces Thermo Scientific Glacios 3 Cryo-TEM

Thermo Fisher Scientific has debuted a next-generation cryogenic transmission electron microscope (cryo-TEM) designed to help scientists understand structural biology with greater clarity. The Thermo Scientific Glacios 3 Cryo-TEM offers researchers a major advancement in 200 kV imaging and structural analysis, according to the company.

Cryogenic electron microscopy (cryo-EM), an advanced technique of flash-freezing biomolecules to visualize them in their native states, enables the Glacios 3 Cryo-TEM to help researchers advance structure-based drug design. Cryo-EM has played a critical role in developing RSV vaccines, GLP-1 therapies, and ongoing research into potential HIV vaccines.

“The Glacios 3 Cryo-TEM opens the door for more institutions and researchers to harness the capabilities of cryo-EM, helping them tackle complex biological questions and enhance therapeutic development,” said Steve Reyntjens, Thermo Fisher Scientific vice president and general manager of life sciences. “This combination of advanced instrumentation and AI-powered workflows represents a step change in how scientists generate insights, which will accelerate the development of life-improving treatments.”

The Glacios 3 Cryo-TEM is equipped with the Thermo Scientific READY System, an integrated suite of technologies that mitigates vibrations and environmental disturbances, which enables installation in a broader range of laboratory spaces by significantly reducing lab renovation complexity. Artificial intelligence (AI)-powered software facilitates cryo-EM workflows to significantly increase throughput and data quality compared to traditional platforms.

New design features improve ease of use, increase productivity, and enhance connectivity to transfer samples without contamination. These features provide access to a range of high-performance cryo-EM techniques, including single-particle analysis, cryo-electron tomography (cryo-ET), and microcrystal electron diffraction (microED).

“When first presented with news of the Glacios 3, I was delighted to learn of the latest developments on its platform,” stated Dr. Steve Smerdon, a professor of structural biology in the University of Birmingham Department of Cancer and Genomic Sciences. “The improvements to the enclosure are particularly impressive, as they will allow greater flexibility in choosing a site for the instrument with potentially substantial reductions in refurbishment and running costs.”

Thermo Fisher Scientific Inc. serves science and generates more than $40 billion in annual revenue. The company helps customers accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, improve patient health through diagnostics, and develop and manufacture life-changing therapies. Its global team delivers a combination of technologies, purchasing convenience, and pharmaceutical services through various brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD.